BioVex raises additional $30m
Woburn firm tries new way to battle cancer
BioVex Inc., a Woburn biotechnology company that raised $40 million in venture capital in March to develop a novel cancer-fighting treatment, today will disclose it has raised another $30 million. (Full article: 532 words)
This article is available in our archives:
Globe Subscribers
FREE for subscribers
Subscribers to the Boston Globe get unlimited access to our archives.
Not a subscriber?
Non-Subscribers
Purchase an electronic copy of the full article. Learn More
- $4.95 1 article
- $9.95 4 articles
- $25.95 Monthly
